Cipla posted poor set of numbers for 1QFY2018. Sales came in at `3,432cr (`3,789cr expected) v/s. `3,566cr in 1QFY2017, a yoy de-growth of 3.5%, mainly driven by the dip in Indian formulation sales. Indian formulation sales registered (`1,271cr) a yoy dip of 12.9%, mainly on the back of GST implementation. On operating front, the EBITDA margins came in at 16.1% (15.5% expected) v/s. 14.8% in 1QFY2017. Thus, the PAT came in at ` 409cr (`346cr expected) v/s. `339cr in 1QFY2017, a yoy growth of 20.6%. We maintain our SELL.
Download Full Report View Full Report in BrowserPlease Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...